Disease activity after discontinuation of disease-modifying therapies in patients with multiple sclerosis in Argentina: data from the nationwide registry RelevarEM

Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis

(2020) Tobias Monschein et al.   JOURNAL OF NEUROLOGY

SUSTAINED DISEASE REMISSION AFTER DISCONTINUATION OF DISEASE MODIFYING TREATMENTS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS

(2020) Matteo Pasca et al.   Multiple Sclerosis and Related Disorders

The Argentinean multiple sclerosis registry (RelevarEM): Methodological aspects and directions

(2019) Juan Ignacio Rojas et al.   Multiple Sclerosis and Related Disorders

Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes

(2019) Hajime Yano et al.   Multiple Sclerosis and Related Disorders

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

(2018) Alan J Thompson et al.   LANCET NEUROLOGY

Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60

(2018) Le H Hua et al.   Multiple Sclerosis Journal

Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis

(2018) Alexander Rae-Grant et al.   NEUROLOGY

Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60

(2018) Le H Hua et al.   Multiple Sclerosis Journal

Multiple sclerosis

(2018) Jiwon Oh et al.   CURRENT OPINION IN NEUROLOGY

Clinical and MRI outcomes after stopping or switching disease-modifying therapy in stable MS patients: a case series report

(2017) Regina Berkovich   Multiple Sclerosis and Related Disorders

Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?

(2016) J. Bonenfant et al.   EUROPEAN JOURNAL OF NEUROLOGY

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

(2016) Ilya Kister et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors

(2016) Gabriel Bsteh et al.   Multiple Sclerosis Journal

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial

(2016) Ludwig Kappos et al.   NEUROLOGY

Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors

(2016) Gabriel Bsteh et al.   Multiple Sclerosis Journal

Stopping immunomodulatory medications in MS: Frequency, reasons and consequences

(2015) W.O. Tobin et al.   Multiple Sclerosis and Related Disorders

Adherence to Multiple Sclerosis Disease-Modifying Therapies in Ontario is Low

(2014) Janice Wong et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Stoppers and non-starters of disease-modifying treatment in multiple sclerosis

(2012) N. Grytten et al.   ACTA NEUROLOGICA SCANDINAVICA

Long-Term Persistence With the Immunomodulatory Drugs for Multiple Sclerosis: A Retrospective Database Study

(2012) Charity Evans et al.   CLINICAL THERAPEUTICS

Long-term outcome of paediatric-onset multiple sclerosis: a population-based study

(2012) Katharine E Harding et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity

(2011) Małgorzata Siger et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Relapses in multiple sclerosis are age- and time-dependent

(2008) H Tremlett et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY